Goldman Sachs Maintains Neutral on Calumet, Raises Price Target to $40

Calumet, Inc.

Calumet, Inc.

CLMT

0.00

Goldman Sachs analyst Neil Mehta maintains Calumet (NASDAQ: CLMT) with a Neutral and raises the price target from $36 to $40.